1. Pharmaceutical Agents for Contractile-Metabolic Dysfunction After Volumetric Muscle Loss
- Author
-
Jennifer McFaline-Figueroa, Albino G. Schifino, Anna S. Nichenko, Magen N. Lord, Edward T. Hunda, Elizabeth A. Winders, Emily E. Noble, Sarah M. Greising, and Jarrod A. Call
- Subjects
Male ,Biomedical Engineering ,Bioengineering ,Biochemistry ,Biomaterials ,Mice, Inbred C57BL ,Mice ,Muscular Diseases ,Pharmaceutical Preparations ,Formoterol Fumarate ,Quality of Life ,Animals ,Regeneration ,Muscle, Skeletal - Abstract
Volumetric muscle loss (VML) injuries represent a majority of military service member casualties and are common in civilian populations following blunt and/or penetrating traumas. Characterized as a skeletal muscle injury with permanent functional impairments, there is currently no standard for rehabilitation, leading to lifelong disability. Toward developing rehabilitative strategies, previous research demonstrates that the remaining muscle after a VML injury lacks similar levels of plasticity or adaptability as healthy, uninjured skeletal muscle. This may be due, in part, to impaired innervation and vascularization of the remaining muscle, as well as disrupted molecular signaling cascades commonly associated with muscle adaptation. The primary objective of this study was to assess the ability of four pharmacological agents with a strong record of modulating muscle contractile and metabolic function to improve functional deficits in a murine model of VML injury. Male C57BL/6 mice underwent a 15% multimuscle VML injury of the posterior hindlimb and were randomized into drug treatment groups (formoterol [FOR], 5-aminoimidazole-4-carboxamide riboside [AICAR], pioglitazone [PIO], or sildenafil [SIL]) or untreated VML group. At the end of 60 days, the injury model was first validated by comparison to age-matched injury-naive mice. Untreated VML mice had 22% less gastrocnemius muscle mass, 36% less peak-isometric torque, and 27% less maximal mitochondrial oxygen consumption rate compared to uninjured mice (
- Published
- 2023